Posted by Adam Awdish on
Human Factor X Purified from Innovative Research was used in the following study:
M. F. A. Karel, T. P. Lemmens, B. M. E. Tullemans, S. J. H. Wielders, E. Gubbins, D. Van Beurden, S. Van Rijt, and J. M. E. M. Cosemans
Cellular and Molecular Bioengineering
October 11, 2021
Atherothrombotic events, such as stroke or myocardial infarction, caused by plaque disruption resulting in the exposure of plaque constituents to blood remain a major cause of death in the western world to this day. The combination of plaque constituents and flowing blood triggers thrombus formation which may lead to vessel occlusion. Some of the major thrombogenic components which contribute to this phenomenon include tissue factor (TF) and collagen type I, both of which are commercially available for use in mimicking atherosclerotic plaque.
Unfortunately, atherosclerotic plaque-collagen appears to have subtle structural differences compared to healthy connective tissue, potentially altering platelet reactivity towards vascular damage. To reduce the chance of altered reactivity, human atherosclerotic plaque tissue is sometimes used as a thrombogenic surface when mimicking arterial thrombosis in in vitro flow assays. However, it is often difficult to achieve a homogenous coating of plaque material on the surface of microfluid assays, which causes issues with being able to reproduce platelet adhesion in models. Researchers in this study tested a novel method for coating plaque materials on microfluid assay glass coverslips that shows promise in helping to create a more consistent and reproducible environment for in vitro thrombosis models.
Related products available from Innovative Research also include: